INTRODUCTION
Kaposi's Sarcoma (KS) is an aggressive cancer of the endothelial cell origin affecting immune compromised patients, the elderly as well as children and adults in Sub-Saharan Africa. KS is the most common cancer overall (men and women) in Namibia, Botswana, Zimbabwe, Zambia, Malawi, Mozambique, Uganda, Ethiopia and parts of South Africa (1) . KS is an AIDS defining malignancy. It is regularly seen as a solid organ transplant associated cancer in Southern Europe, the Mediterranean region, Turkey and Saudi Arabia (2). Chang et al. identified Kaposi's Sarcoma-associated Herpes Virus (KSHV) in any and all forms of KS (3) . For lack of known tumor-specific target pathways, KS is treated with cytotoxic chemotherapy, now predominantly liposomal doxorubicin (Doxil™). Although, initial response rates are reasonable, subsequent failures are not uncommon (4) . Drug resistance has also been documented. Doxil™ is associated with toxicity and has a lifetime dose limit. This motivated our experiments to establish a novel animal model for drug evaluation and to explore the PI3K/Akt/mTOR pathway as a new target of intervention in KS.
Morphologically, KS lesions appear as flat dermal 'patches' upon initial presentation. As the lesion progresses, it goes from patch to plaque to nodule and the initial red color takes on a darker, purplish hue. The characteristic color of these lesions is indicative of the high degree of vasculogenesis and angiogenesis associated with KS. Angiogenesis in KS begins even before the formation of a visible lesion. 100% of the KS tumor cells carry KSHV and express the KSHV latency associated nuclear antigen (LANA) as the defining biomarker for KS (5, 6) . The tumor cells also express other viral proteins, which promote tumor cell growth cell-autonomously or through induction of soluble factors, which act through autocrine and paracrine mechanisms.
vGPCR is the KSHV homolog to human IL8 receptor; it can signal in the absence of ligand binding, thus resulting in a constitutively active state (7) (8) (9) . vGPCR can activate phosphoinositide-3-Kinase (PI3K) as well as induce Vascular Endothelial Growth Factor (VEGF) (10) .
Other viral signaling molecules, which can activate PI3K signaling, include K1 and K15 (11, 12) .
As multiple (K1, K15, vGPCR) viral signaling molecules converge on the PI3K pathway, we reasoned that KS is addicted to this pathway and that kinases within this pathway represent promising drug targets.
PI3K is activated by membrane receptor signaling and phosphorylates its downstream target Akt. Phosphorylated Akt in turn activates the mTOR kinases, which have multiple targets that support cell growth (reviewed in (13, 14) ). We, along with other groups, have shown that the PI3K/Akt/mTOR pathway is constitutively activated in KS-infected cells as well as in vGPCR and K1 driven cell culture models (12, (15) (16) (17) (18) .
Clinical observations also supported the importance of the PI3K/Akt/mTOR pathway in KS. Stallone et al. (19) reported that switching the immune suppressive regimen of renal transplant patients from CyclosporinA, which inhibits cyclophillin in T-cells, to rapamycin (sirolimus), which inhibits mTOR (20) , resulted in regression of KS lesions. Others have reported similar cases (21) (22) (23) ; a few exceptions have also been noted (24, 25) . Most recently we completed a pilot study of AIDS-KS and found long-term disease stabilization or partial responses in 6 of 7 (85%) HIV-positive patients (26). These clinical studies allowed for two alternative hypotheses as to the mechanism of rapamycin and other allosteric mTOR inhibitors (everolimus, temsirolimus), the so-called rapalogs (reviewed in (27) renal cell cancer and temsirolimus in mantle cell lymphoma (28) (29) (30) . These anti-tumor effects could be impacting the tumor cell directly or the supporting vasculature. Unique to KS both the tumor cell itself and the tumor-feeding blood vessels are of endothelial origin.
To decide among these competing hypotheses we established a novel mouse model of KS, which is dependent on the KSHV virus, and used it to evaluate a battery of structurally different, FDA approved mTOR inhibitors: rapamycin/ Sirolimus, everolimus/ RAD-001 and Temsirolimus/ CCI-779. As controls we used Cyclosporine A and FK506 (Tacrolimus), which is a macrolide that is structurally related to rapamycin, but does not inhibit mTOR (31) . The latter control drugs modulate the immune status as efficiently as rapamycin, but have no activity against mTOR. We found that all three rapalogs were equally effective in multiple KS models.
Rapalogs inhibited VEGF-1 secretion and arrested growth in immune deficient mice by reducing intra-tumor ribosomal S6 phosphorylation, tumor growth and neoangiogenesis. In this model rapamycin was superior to doxorubicin.
METHODS
Cell culture All cell lines were cultured in DMEM supplemented with 100 μg/ml streptomycin sulphate, 100 U/ml penicillin G (Life Technologies, Carlsbad, CA, USA), and 10% FBS at 37°C in 5% CO 2 . Cell lines were obtained from the ATCC or derived in our laboratory.
The cells have been tested and authenticated. The method used was whole genome Affymetrix 6.0 SNP array. The cells were last tested by the aforementioned method at submission within receipt or resuscitation from stock. The L1T2 cell line will be submitted to the ATCC.
Quantitative PCR for KSHV Genome Genomic DNA was extracted using Wizard SV Genomic DNA Purification System, as per manufacturer's protocol (Promega, Madison, WI) and quantitative PCR (qPCR) was used to detect the viral genome in the different KS cell lines as per our previous publications (32) .
CGH Analysis
Genomic DNA was extracted as above and hybridized to the 6.0
GeneChip Human Mapping Array that uses >906 600known SNP and 946 000 CNV markers (Affymetrix). Data analysis was performed using Partek Genomics Suite as described previously (33) , and normalized to tert-immortalized human vein endothelial cell (HUVEC).
Immunofluorescence Cells were cultured overnight on glass coverslips in 6-well plates (Falcon-BD Biosci. Inc, San Jose, CA). They were then washed in PBS followed by protocol for immune fluorescence as described (34) . Primary mouse anti-LANA (1:600 dil.) (Novocastra Lab Blood Rapamycin Quantification Blood was collected from the animals by cardiac puncture 48hrs after the last intra-peritoneal injection of Rapamycin at either 2.5 mg/kg or 5 mg/kg dose. Care was taken to ensure that blood was directly collected into EDTA-coated tubes (BD, Franklin Lakes, NJ) to prevent any coagulation. Rapamycin levels were determined from whole blood by HPLC-MS-MS using Nova_Pak® columns (Waters Corp, Milford, MA) offering sensitivity in the 2-50 ng/ml range.
Immunohistochemistry Tumors were removed and processed as per (17) 
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(Sigma Aldrich, St. Louis, MO). Sections were imaged, PAS staining quantified using FRIDA and significance determined, as above.
VEGF Quantification VEGF levels in the culture supernatants were determined using commercially available VEGF ELISA assay as per manufacturer's recommendations (PeproTech, Rocky Hill, NJ). The biological activity of secreted VEGF (supplemental figure 1) was ascertained by sprouting assay as described (37) . 
Rapamycin is efficacious against KS xenograft tumors in vivo
To test the hypothesis that rapalogs have direct anti-tumor activity against KS and that this activity is independent of any immune modulating properties that these agents may also have, we treated established xenografts in C.B.17-Pkrdc SCID mice that lack any immune effector cells with rapamycin and its various analogs. First, we tested TIVE-E1 and TIVE-L1 cells, which had previously been established as model systems to study KS pathogenesis in nu/nu mice (44) . TIVE E1 and L1 represent two independent clones of telomerase-immortalized, KSHV To establish equivalency amongst the different rapalogs we also tested temsirolimus and everolimus in the L1T2 system. Each resulted in significant tumor inhibition. We also tested the ATP-competitive mTOR inhibitor PP242 (table 1) . This resulted in tumor reduction, but was not superior to allosteric rapalogs. FK506, which is structurally similar to rapamycin, and which like rapamycin binds FKBP (but not mTOR), had no activity (table 1). Table 1 is a summary of all the studies we conducted. These show that rapalogs are efficacious against tumors, irrespective of whether they were isolated from KS biopsies (SLK) or generated following de novo infection of endothelial cells (E1, L1, L1T2). Single agent rapalogs, irrespective of their particular structure, resulted in prolonged (up to 130 days) growth inhibition. Of note, each experiment was conducted in parallel with a similar size group of mock treated animals, which received the same cell aliquot. The group size n in table 1 refers only to the size of the experimental group.
In total we observed significant raplog-dependent tumor inhibition in 85 animals. Rapalog dosing presents a significant challenge in the clinic, especially considering that rapalogs are metabolized by the cytochrome P450 family members in the liver (47) . Even in culture, the IC50 for rapamycin may vary more than 1000-fold between cancer cell lines (48).
The reason is unknown and may have as much to do with drug transport as with pathway resistance mutations. P450 is expressed by the tumor endothelial cells within KS lesions (Roy and Dittmer, unpublished) . Therefore, we optimized the dosing regimen required to obtain therapeutic drug trough levels, while minimizing toxicity. Note that our dosing is rather infrequent compared to other experimental designs (16, 49) , which require daily dosing. At 5mg/kg doses of rapamycin the animals exhibited weight loss, lethargy and had to be sacrificed despite robust inhibition of tumor progression. At 1.5mg/kg, the animals remained healthy throughout extended treatment, but anti-tumor activity was lost (data not shown). Based on these data we established the optimal dose for long-term rapamycin treatment in C.B.17.PKRD scid mice at 2.5 mg/kg 3 times a week. Next, we assessed the actual levels of Rapamycin in the blood stream of the animals. Figure 2 , panel F shows that at 2.5mg/kg doses we are able to maintain a steady level of drug in the blood compared to 5mg/kg (figure 2, panel E) where blood levels spike early on and presumably cause drug toxicity. In summary, we established the efficacy of multiple, chemically distinct rapalogs (sirolimus/rapamycin, temsirolimus, everolimus), and the ATPcompetitive mTOR inhibitor PP242 in four distinct xenograft models of KS. We established 2.5 mg/kg 3 times a week as a low intensity regimen, which resulted in long-term (> 60 days) growth suppression and showed that this dosing regimen leads to sustained, systemic trough levels of 20 ng/ml, which was the target trough levels in recent clinical trials of this drug family (26). 
Rapamycin inhibits phosphorylation of mTOR targets S6-ribosomal protein and 4E-Binding Protein in vivo
Having extensively validated our tumor model, we used it to elucidate the mechanism of action of allosteric rapalogs in KS. Phosphorylation of ribosomal S6 (S6R) protein is considered a robust readout for mTOR activation. We treated L1T2 cells with rapamycin (5 μM corresponding to 4.5μg/ml) in culture and measured S6 phosphorylation. Figure 4 shows immunofluorescence staining for total (panels A and D) and phosphorylated S6R (pS6R) (panels B, E for pS6R (Ser235/236) and panels C, F for pS6R (Ser240/244)). As expected S6 is expressed at high levels in L1T2 cells and heavily phosphorylated at both composite sites (figure 4, panels A, B and C). Upon treatment with rapamycin, total S6 expression remained unchanged, while S6 phosphorylation was completely abolished (without loss of cell viability).
This demonstrates that rapalogs inhibit their molecular targets in our KS-tumor model. (51) (52) (53) . This phenotype is recapitulated in our murine model. Rapalogs are known to inhibit endothelial-cell mediated tumor neo-angiogenesis in addition to direct tumor growth (54, 55) . We therefore hypothesized that some of the KS-specific targets of rapamycin are paracrine growth factors involved in tumor vasculature development.
Because of the endothelial cell lineage of KS tumors, these same growth factors can also function in an autocrine manner, which may explain the increased sensitivity of KS to rapalogs.
VEGF is a key angiogenesis-promoting factor secreted by KS and other tumor cells.
TIVE-E1, -L1, SLK and L1T2 cells all secrete VEGF, as detected in the culture supernatant. We measured between 2,000 -4,000 pg/ml in the supernatant KS-like cells over a 48-hour period.
By comparison, KSHV-infected lymphoma cell lines secreted 200 -400 pg/ml in the same, luminex-based, assay. The cells secreted similarly high levels of IL-6 and IL-8 (Roy and Dittmer, unpublished). Rapamycin down regulated levels of VEGF secreted by TIVE-L1 cells in culture ( figure 5, panel A) . We conducted a time course followed by drug washout experiment to assess both the production and accumulation of VEGF in culture supernatant. We detected levels of secreted VEGF (isoform A) in cells treated with 0.5μM (0.45μg/ml) and 5μM (4.5ug/ml) rapamycin over 96-hours ( figure 5, panel A) . Upon drug withdrawal, the cells recovered slowly and gradually increased VEGF secretion. Similar results were noted for TIVE-L1, SLK and L1T2 cells (data not shown). For KSHV infected BCBL-1 cells, we found that conditioned media from rapamycin treated cells no longer supported HUVEC tubule formation (supplemental figure 1) . 
This demonstrates that rapamycin inhibits biologically active VEGF, which is an autocrine growth factor in KS (56).
The xenograft model constitutes a much more demanding setting than in vitro culture and requires cancer cells to establish and maintain an optimal microenvironment for survival.
We hypothesized that reduction of growth factors by rapalogs would have a pronounced impact on tumor progression. To address this, we utilized PAS staining, which marks the vasculature directly, rather than relying on just one particular biomarker protein, thereby detecting the overall physiological impact (57, 58) . Rapamycin resulted in a sustained tumor vasculature defect 
Rapamycin and Doxorubicin combination therapy
Having demonstrated single-agent efficacy of multiple rapalogs against KS, we explored the efficacy of rapamycin in the adjuvant setting. Specifically, we wanted to test the hypothesis that adding doxorubicin to rapamycin would result in increased cytotoxicity. We confirmed this hypothesis in the cell culture model of PEL (supplemental Figure 2) (27) . Here, we tested the hypothesis that mTOR inhibitors have anti-tumor activity against KS, and we describe a new mechanism that could explain the extraordinary sensitivity of KS to rapamycin. This work was predicated on development of a new human tumor model of KS, which is robust, fast and mimics all the phenotypes associated with the human tumor (figure 1). It was driven by the insights that (i) KS is an endothelial cell lineage tumor (42, 61, 62) , (ii) KS is dependent on autocrine and paracrine growth factors, (iii) extensive neoangiogenesis and, (iv) rapalogs stymy tumor growth in common cancers by inhibiting the host endothelial cells comprising the tumor vasculature and microenvironment as well as through direct inhibition of tumor cell activity (14) .
For the purpose of this discussion we define rapalogs functionally as inhibitors of mTOR, as opposed to FK506, which has a similar chemical structure as rapamycin, but does bind to or inhibit mTOR. All rapalogs tested induced tumor regression of preformed KS-like human tumors in our xenograft model ( figure 2, table 1 ). Rapalog efficacy did not depend on immune system modulation, since the host animals were deficient for B, T and NK cells and since we achieved long-term, sustained responses with a 3x per week dosing regimen. Rapalog efficacy did not depend on the presence of KSHV, since KSHV-negative SLK cell tumors were also inhibited. This is expected since SLK cells exhibit the same signs of PI3K/Akt/mTOR activation, i.e. 
phosphorylation of key residues, as KS tumors (36) , and as KSHV-induced KS cell lines.
Rapalogs decreased phosphorylation of S6 ribosomal protein and 4EBP-1 in vivo (figure 4), demonstrating that they inhibit the intended molecular targets downstream of mTOR. The antitumor effect was reversible in vivo: upon withdrawal of the rapalogs the tumors grew back uniformly (supplemental figure 3) . In contrast, two chemically related drugs Cyclosporine-A (data not shown) and FK506 had no anti-tumor effect. This is particularly interesting since FK506 like rapamycin also binds to FKBP12, but cannot bind mTOR (63). It supports the specificity of action of the rapalogs. The ATP-competitive inhibitor PP242 also inhibited tumor progression in vivo, but was not superior to the allosteric mTOR inhibitors. This validates mTOR as a bona-fide drug target in KS and provides a solid biological rationale for future clinical trials.
We uncovered a novel mechanism of action for mTOR inhibitors that is specific to KS.
The rapalogs inhibited VEGF secretion by the KS tumor cells (figure 3) as well as VEGF secretion in KSHV-dependent lymphomas (supplemental figure 2) . We surmise that the translational arrest induced by mTOR inhibition is not universal, but preferentially affects autocrine growth factors of endothelial lineage cells and KS tumor cells. This is analogous to the situation in PEL, where we showed previously that rapamycin stopped lymphoma growth by inhibiting the essential autocrine growth factors IL6 and IL10 (17) . This may explain the differential response of different human cancers to rapalogs. Cancers, like KS, that still depend heavily on pro-angiogenic and growth factors to sustain elevated PI3K signaling are susceptible to mTOR inhibitors. Cancers that evolved growth factor independence such as hormone resistant prostate cancer or estrogen receptor negative breast cancer may be less responsive to mTOR inhibitors.
Finally, we explored the combination therapy of rapamycin with the prototypic cytostatic drug, doxorubicin, which represents the current standard of care for KS. We did not find any 2 ) developed in >= 50% of animals. Each treatment group was compared to a control, vehicle group of similar number of animals that was inoculated simultaneously with the same number of tumor cells. Vehicletreated animals (control group) require euthanasia between day 20 -40. (i)
"Reduction in volume" shows the % reduction in mean tumor volume in the drugtreated group compared to the vehicle treated group at time point of maximum difference. Typically this was the day when >50% of tumors in the control group grew to 2000 mm 2 and/or required euthanasia. (ii) "progression free" shows the number of days that the animals in the drugtreatment arm remain on study without exponential tumor growth requiring euthanasia or until the experiment was terminated because reduction in tumor volume between matched control and treatment group was significant to p<=0.05. (iii)
"n" is the number of animals per drug-treated group. In each experiment these are paired with 5-6 vehicle treated animals that received tumor cells on the same day and from the same passage to allow for direct comparison and calculation of relative reduction in volume. 
